Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma Plc LSE:MTPH London Ordinary Share GB00BKT14T00 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  1.50 4.62% 34.00 492,856 15:58:07
Bid Price Offer Price High Price Low Price Open Price
33.00 35.00 34.50 31.30 32.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.31 -10.92 -50.00 21
Last Trade Time Trade Type Trade Size Trade Price Currency
16:44:42 O 25,000 35.50 GBX

Midatech Pharma (MTPH) Latest News

More Midatech Pharma News
Midatech Pharma Investors    Midatech Pharma Takeover Rumours

Midatech Pharma (MTPH) Discussions and Chat

Midatech Pharma Forums and Chat

Date Time Title Posts
15/1/202115:25Midatech Pharma (MTPH) sees 10-fold increase1,690
12/12/202008:58Midatech Pharma 3
21/7/202011:16 Midatech Pharma Plc9
30/4/201920:51Midatech Pharma (MTPH) One to Watch 2
03/1/201712:41Midatech Pharma PLC181

Add a New Thread

Midatech Pharma (MTPH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-22 17:44:4335.5025,0008,875.00O
2021-01-22 16:18:0833.344,6351,545.08O
2021-01-22 16:17:3633.346,7072,235.78O
2021-01-22 16:10:2534.005,0001,700.00O
2021-01-22 15:58:2233.95526178.58O
View all Midatech Pharma trades in real-time

Midatech Pharma (MTPH) Top Chat Posts

Midatech Pharma Daily Update: Midatech Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTPH. The last closing price for Midatech Pharma was 32.50p.
Midatech Pharma Plc has a 4 week average price of 25p and a 12 week average price of 24.50p.
The 1 year high share price is 86.50p while the 1 year low share price is currently 1.90p.
There are currently 63,073,852 shares in issue and the average daily traded volume is 368,906 shares. The market capitalisation of Midatech Pharma Plc is £21,445,109.68.
alexios1201: Emergex Vaccines Provides an Update on Agreement with Midatech Pharma22nd November 2016/Oxford, UK, 22 November 2016 – Emergex Vaccines Holding Limited ("Emergex"), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that it has paid an upfront technology access fee and option payment of £450,000 to Midatech Pharma (AIM: MTPH, NASDAQ: MTP), under the terms of the contract. This follows the licence granted to Emergex from Midatech Pharma, which was announced in January this year.The exclusive licensing agreement covers the use of Midatech's proprietary gold nanoparticle platform in the development of vaccines for influenza, meningitis, bacterial pneumonia, Ebola virus, Marburg virus and viruses within the Arbovirus class, such as Zika and Dengue. This is the first deployment of Midatech's gold nanoparticles as a conventional vaccine for infectious diseases.Under the agreement, the licence, together with the Service and Manufacturing Agreement for both the synthesis and development manufacturing of cGMP material for clinical trials, was novated from Emergex Vaccines Limited to a related entity, Emergex Vaccines Holding Limited ("Emergex"), a private UK biotechnology company focused on developing synthetic T-cell vaccines against new and emerging infectious diseases.Midatech will continue to be entitled to receive certain milestone and royalty payments, as well as service fees, as part of the arrangement
alexios1201: Emergex Vaccines signs Collaboration Agreement with Brazil's Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine5th January 2021/Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of BrazilBio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world's most respected public health researchinstitutionsAbingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited ('Emergex', or 'the Company'), a company tackling major global infectious disease threats through the development of synthetic 'set point' vaccines which prime the T-Cell immune response, today announces that it has signed a collaboration and development agreement with the Institute of Technology on Immunobiologicals (Bio-Manguinhos) of the Oswaldo Cruz Foundation (Fiocruz) in Brazil to develop a COVID-19 vaccine using Emergex's next generation synthetic T-Cell vaccine technology.The agreement provides a framework under which both parties will work together to progress certain immunotherapeutic programmes, including a vaccine candidate for COVID-19, through a regulatory pathway for the Brazilian National Health Service. Emergex will also support the performance of studies, including clinical trials, and to manufacture, market, promote and distribute certain infectious diseases vaccines within the National Health Service of Brazil.Emergex has already completed preclinical development work including toxicology and immunoproteomic research into the MHC Class I peptide expression library for cell surface expressed peptides on SARS-Cov-2 infected cells, which define the repertoire of an effective T-Cell immune response to the COVID-19 disease.In August 2020, a previous research collaboration between Emergex and Bio-Manguinhos / Fiocruz resulted in the determination of the MHC CD8 T-Cell epitope expression library for Fiocruz's commercial yellow fever vaccine.Bio-Manguinhos / Fiocruz and Emergex will share initial set up and development costs. Further financial details have not been disclosed
ukneonboy: GERMAIN09 I just think that you are posting sh*te across multiple ADVFN BB's to try to "ramp up" the MIDATECH PHARMA share price !!! Seriously, fellah, don't mess about ............. just post MIDATECH has got a cure for Cancer & for CoVid19 and you'll be minted !!!
kingston78: I was surprised that the 40p rise did not sustain, dropping to 29p so quickly. There must have been a lot of short term profit taking. Long term holders should not fear the short term trends, as we have seen elsewhere that some share prices rise by upto 10 times.
kingston78: The share price has a habit to spike sharply upwards. I will not be surprised if it will challenge 80 p level in the coming days.
aimmafia: I'm not invested here, well done. DNL and MTPH are going to do very well
tommy robinson: Just because ramping activity might be taking place in pockets, it doesn't mean MTPH is some kind of dog share. Just watch the investor presentation from a few weeks ago and make your own mind up. The ramper in question is suggesting a 60-70p target, which we've hit a number of times in recent history. So not too much of an exaggeration.
kingston78: I am sure that the share price will double from here in a short space of time. Buy buy buy tomorrow.
kingston78: The share price has bottomed out. It is time to buy for a strong rise.
mubz: What is interesting is that this chap at Paul Hasting law firm- Deyan P. Spiridonov is a member of the firm's Mergers & Acquisitions practice. So have Secura Bio done this in order to trash MTPH share price and then put in a hostile bid to takeover Please be advised that in the event that Secura Bio refuses to withdraw its purported termination notice, Midatech and Midatech Limited will vigorously pursue any and all available remedies, including claims for monetary damages based on Secura Bio's intentional wrongdoing. Midatech and Midatech Limited also reserve all rights in law and equity against Secura Bio and its agents, including, without limitation, the right to pursue tort claims (and a recovery of fees and costs in the UK) resulting from Secura Bio's intentional efforts to cause harm to and to adversely affect Midatech's market position.
Midatech Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Midatech P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210123 01:45:37